Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?

Detalhes bibliográficos
Autor(a) principal: Francisco, A. R. Gaspar Lopes
Data de Publicação: 2017
Outros Autores: Alves, D., Gonçalves, I. S., Menezes, M. N., Silva, G. Lima da, Guimarães, T., David, C., Braga, J., Guerra, L., Pinto, Fausto J., Almeida, A. G.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/35015
Resumo: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017.
id RCAP_60001638ca310c40f6a55690b05407f2
oai_identifier_str oai:repositorio.ul.pt:10451/35015
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?Hematological diseasesImatinib mesylateProtein-tyrosine kinase inhibitorCardiotoxicityNilotinibPublished on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017.Introduction: Chemotherapy-induced cardiotoxicity is a growing concern. The true cardiotoxic impact of new drugs such as tyrosine kinase inhibitors is unknown, especially the ones used for chronic myeloid leukaemia. We aim to evaluate nilotinib and imatinib induced cardiotoxicity. Methods: Single-center prospective study of consecutive patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors during 2015. Patients underwent an initial clinical, laboratorial and echocardiographic evaluation, repeated one year after therapy initiation. Results: Eleven patients were included [60.0 (11) years, 63.6% of males; 7 patients treated with imatinib and 4 with nilotinib]. After one year of follow-up, all patients remained in functional NYHA class I, with a similar Minnesota quality of life score [21 (20) vs. 21 (19), p = NS]. Also there was no difference in the biomarkers evaluated: cystatin-C [0.9 (0.2) vs. 0.8 (0.2) mg/L, p = NS; NT-proBNP 46.0 (45.0) vs. 42.0 (34.0) pg/mL, p = NS]. Previous to the TKI treatment, all patients had normal left ventricular ejection fraction (LVEF) [(median 67% (63–69)], without structural abnormalities. During the follow-up, there weren't differences regarding the LVEF, left atrium volume, E/A ratio, deceleration time, septal e', lateral e', E/e' ratio and tricuspid annular plane systolic excursion. With regard to myocardial deformation, all patients presented normal values of longitudinal, circumferential and radial strain in the baseline study, without changes during follow-up [DML -21.3 (6, 1) vs. -21.7 (6.0)%, p = NS; DMC -20.0 (9.3) vs. -22.3 (5.3)%, p = NS; DMR 36.9 (21.3) vs. 39.2 (19.2)%, p = NS]. In addition, there were no differences between the two tyrosine kinase inhibitors used, considering all the aforementioned variables. Conclusion: No clinical, laboratory or echocardiographic evidence of nilotinib and imatinib induced cardiotoxicity was observed, even when myocardial deformation analysis was performed. However, these results should be confirmed in larger studies, ideally multicentre, given the low incidence of chronic myeloid leukaemia.Oxford University PressRepositório da Universidade de LisboaFrancisco, A. R. Gaspar LopesAlves, D.Gonçalves, I. S.Menezes, M. N.Silva, G. Lima daGuimarães, T.David, C.Braga, J.Guerra, L.Pinto, Fausto J.Almeida, A. G.2018-10-12T10:58:23Z20172017-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/35015engEuropean Heart Journal, Volume 38, Issue suppl_10195-668X10.1093/eurheartj/ehx493.P6161info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:30:40Zoai:repositorio.ul.pt:10451/35015Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:49:35.109581Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?
title Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?
spellingShingle Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?
Francisco, A. R. Gaspar Lopes
Hematological diseases
Imatinib mesylate
Protein-tyrosine kinase inhibitor
Cardiotoxicity
Nilotinib
title_short Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?
title_full Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?
title_fullStr Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?
title_full_unstemmed Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?
title_sort Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?
author Francisco, A. R. Gaspar Lopes
author_facet Francisco, A. R. Gaspar Lopes
Alves, D.
Gonçalves, I. S.
Menezes, M. N.
Silva, G. Lima da
Guimarães, T.
David, C.
Braga, J.
Guerra, L.
Pinto, Fausto J.
Almeida, A. G.
author_role author
author2 Alves, D.
Gonçalves, I. S.
Menezes, M. N.
Silva, G. Lima da
Guimarães, T.
David, C.
Braga, J.
Guerra, L.
Pinto, Fausto J.
Almeida, A. G.
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Francisco, A. R. Gaspar Lopes
Alves, D.
Gonçalves, I. S.
Menezes, M. N.
Silva, G. Lima da
Guimarães, T.
David, C.
Braga, J.
Guerra, L.
Pinto, Fausto J.
Almeida, A. G.
dc.subject.por.fl_str_mv Hematological diseases
Imatinib mesylate
Protein-tyrosine kinase inhibitor
Cardiotoxicity
Nilotinib
topic Hematological diseases
Imatinib mesylate
Protein-tyrosine kinase inhibitor
Cardiotoxicity
Nilotinib
description Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017.
publishDate 2017
dc.date.none.fl_str_mv 2017
2017-01-01T00:00:00Z
2018-10-12T10:58:23Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/35015
url http://hdl.handle.net/10451/35015
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv European Heart Journal, Volume 38, Issue suppl_1
0195-668X
10.1093/eurheartj/ehx493.P6161
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134428621963264

Registros relacionados